Nifedipine and telmisartan for the treatment of hypertension: The TALENT study

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 12, 2011, Pages 1499-1503

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

adverse events; blood pressure; combination treatment; nifedipine; telmisartan

Indexed keywords

AMLODIPINE; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; NIFEDIPINE; TELMISARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; NIFEDIPINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 82755161189     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.155     Document Type: Article

References (23)

1. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27, 2121-2158 (2009).
2. Mancia G, De Backer G, Dominiczak A et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25, 1105-1187 (2007). (Pubitemid 46924065)
3. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur. Heart J. 28, 2375-2414 (2007).
4. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 24, 287-296 (1994). (Pubitemid 24278057)
5. van der Lee R, Kam KL, Pfaffendorf M, van Zwieten PA. Differential time course of the vasodilation action of various calcium antagonists. Fundam. Clin. Pharmacol. 12, 607-612 (1998). (Pubitemid 29535483)
6. Mancia G. The sympathetic nervous system in hypertension. Bjorn Folkow Award Lecture. J. Hypertens. 15, 1553-1565 (1997). (Pubitemid 28029649)
7. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92, 1326-1331 (1995).
8. Grossman E, Messerli FH. Effect of calcium antagonists on plasma norepinephrine levels, heart rate and blood pressure. Am. J. Cardiol. 80, 1453-1458 (1997). (Pubitemid 27523026)
9. Masuo K, Mikami H, Ogihara T, Tuck ML. Metabolic effects of long-term treatments with nifedipine-retard and captopril in young hypertensive patients. Am. J. Hypertens. 10, 600-610 (1997). (Pubitemid 27293475)
10. Terpstra WF, May JF, Smit AJ, de Graeff PA, Crijns HJ. Effects of nifedipine on carotid and femoral arterial wall thickness in previously untreated hypertensive patients. Blood Press. Suppl. (Suppl. 1), 22-29 (2003). (Pubitemid 36681969)
11. Mancia G, Brown M, Castaigne A et al.; for the INSIGHT Study Group. Outcomes with nifedipine GITS or co-amilozide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension 41, 431-436 (2003 (Pubitemid 36314612)
12. Ruilope LM, Rosei EA, Bakris GL et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press. 14, 196-209 (2005). (Pubitemid 41387809)
13. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 61, 1501-1529 (2001). (Pubitemid 32783749)
14. Derosa G, Cicero AF, DAngelo A et al. Telmisartan and irbesartan therapy in Type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens. Res. 29(11), 849-856 (2006). (Pubitemid 46062116)
15. Derosa G, Fogari E, DAngelo A et al. Metabolic effects of telmisartan and irbesartan in Type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J. Clin. Pharm. Ther. 32(3), 261-268 (2007). (Pubitemid 46699517)
16. Fogari R, Zoppi A, Ferrari I et al. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm. Metab. Res. 41(12), 893-898 (2009).
17. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, Type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens. Res. 27(7), 457-464 (2004). (Pubitemid 39157547)
18. Fogari R, Mugellini A, Zoppi A et al. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J. Cardiovasc. Pharmacol. Ther. doi:10.1177/1074248410395018 (2011) (Epub ahead of print).
19. Mancia G, Parati G, Bilo G, Choi J, Kilama MO, Ruilope LM; TALENT investigators. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. J. Hypertens. 29(3), 600-609 (2011).
20. Fogari R, Derosa G, Zoppi A et al. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am. J. Hypertens. 20(4), 417-422 (2007). (Pubitemid 46441757)
21. Derosa G, Cicero AF, Bertone G et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with Type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. Clin. Ther. 26(8), 1228-1236 (2004). (Pubitemid 39445345)
22. Fogari R, Preti P, Zoppi A et al. Effect of telmisartan/ hydrochlorothiazide combination versus nifedipine GITS on ambulatory blood pressure and sympathetic activation. Am. J. Hypertens. 18, 577-583 (2005). (Pubitemid 40692422)
23. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J. Hum. Hypertens. 23, 503-511 (2009)